Incyte Corporation

INCY · Moat type: REGULIERUNG

MoatScore

10/10

Fair Value

195 USD

Margin of Safety

+40.2 %

Rating

STARK

Incyte Corporation develops and markets oncological and anti-inflammatory therapeutics — revenue is generated primarily through prescription specialty pharmaceuticals (including JAK inhibitors) and licensing income from partners, with patent protection and regulatory approvals forming the essential barriers to entry.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.